Wealth Enhancement Advisory Services LLC Boosts Holdings in GSK plc (NYSE:GSK)

Wealth Enhancement Advisory Services LLC lifted its holdings in GSK plc (NYSE:GSK - Free Report) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 174,688 shares of the pharmaceutical company's stock after purchasing an additional 13,039 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in GSK were worth $5,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Indiana Trust & Investment Management Co lifted its holdings in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after buying an additional 500 shares during the period. Sierra Ocean LLC purchased a new stake in GSK during the fourth quarter valued at $32,000. Parkside Financial Bank & Trust lifted its holdings in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in GSK in the fourth quarter valued at about $40,000. Finally, Golden State Wealth Management LLC purchased a new position in GSK in the fourth quarter worth about $38,000. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock traded up $0.07 during trading hours on Friday, reaching $41.22. 3,225,577 shares of the company traded hands, compared to its average volume of 4,818,059. GSK plc has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company has a market cap of $85.05 billion, a P/E ratio of 25.92, a P/E/G ratio of 1.12 and a beta of 0.51. The firm has a 50-day moving average price of $37.59 and a 200 day moving average price of $36.39.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same period in the previous year, the firm earned $0.43 EPS. The business's quarterly revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is presently 86.60%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research reports. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday. Finally, Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, GSK presently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.